Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-14 (marketbeat.com)
Causeway Capital Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB)
Causeway Capital Management LLC acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 281,702 shares of the biotechnology company's st
Read more
2024-09-26 (stocknews.com)
BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket
Biogen Inc.(NASDAQ:BIIB): Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen( BIIB), Royalty Pharma( RPRX), and BioMarin
Read more
2024-08-27 (fingerlakes1.com)
The Best of Boston: A Guide to Senior Living in 2024
The Best of Boston: A Guide to Senior Living in 2024 Travel
Read more
2024-08-12 (realtid.se)
Xbrane Biopharma must out-license drugs to secure financing
Biotech company Xbrane Biopharma has begun a process of out-licensing Xdivane and XB003 to secure financing until the second quarter of 2025, when it is expected to reach positive operating cash flow. It appears from a press release.
Read more
2024-08-07 (pharmavoice.com)
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.
Read more
2024-01-16 (pharmamanufacturing.com)
Bayer sells stroke asset to JiXing
Fresh off a $162 million series D funding round, the Chinese biotech strikes a deal for a phase 2 plasminogen activator
Read more
2023-12-04 (necn.com)
Biotech startup raises nine-figure round, one of the biggest of 2023
Biotech startup raises nine-figure round, one of the biggest of 2023
Read more
2023-09-29 (e-fundresearch.com)
SEB Global High Yield Fund
The abrdn SICAV I – Frontier Markets Bond Fund (ISIN LU1003376065) closed on September 25th
Read more
2023-09-20 (pharmaceutical-technology.com)
ADDF invest in BrainScope for Alzheimer’s prediction biomarker
The neurotech will receive the investment in Series B equity financing round to invest in Alzheimer’s disease research.
Read more
2023-09-05 (endpts.com)
Biogen secures $1.5B loan to fund Reata buyout, with three-year repayment schedule baked in
Biogen has lined up a $1.5 billion term loan to fund its $7.3 billion acquisition of Reata Pharmaceuticals. The company had made clear its intentions to finance the acquisition with both cash and debt in its August announcement.
Read more
2022-12-30 (devdiscourse.com)
US Domestic News Roundup: Horse racing-US horse racing authority seeks to vacate 'unconstitutional' ruling; Biden signs $1.66 trillion FY 2023 government funding bill and more | Business
Read more about US Domestic News Roundup: Horse racing-US horse racing authority seeks to vacate 'unconstitutional' ruling; Biden signs $1.66 trillion FY 2023 government funding bill and more on Devdiscourse
Read more
2019-10-24 (labiotech.eu)
German Alzheimer's Drug Backed with €43M After Biogen's Surprise Turnaround
Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease.
Read more